about
P1365
Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study.Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and ChlorthalidoneNoninferiority trialsInformative noncompliance in endpoint trialsUnanswered ethical and scientific questions for trials of invasive interventions for coronary disease: The case of single vessel diseaseCurrent Controlled Trials in Cardiovascular Medicine: a new journal for a new age (http://cvm.controlled-trials.com)Current Controlled Trials: an opportunity to help improve the quality of clinical researchDebate: Unstable angina - When should we intervene?Debate: When should we intervene in unstable angina - Time for an old look?Implications of recent hypertension trials for the generalist physician: whom do we treat, and how?Debate: Subgroup analyses in clinical trials: fun to look at - but don't believe them!Debate: A subversive view of subsets - a dissident clinician's opinionImportance of the TIMI frame count: implications for future trialsMedical errors: how the US Government is addressing the problemWhy do antioxidants fail to provide clinical benefit?Genetic counselling for hypertrophic cardiomyopathy: are we ready for it?Use of intravenous antiarrhythmics to identify concealed Brugada syndromeLong-term outcome after coronary stentingClinical trials in developing countries: Discussions at the '9th International Symposium on Long Term Clinical Trials', London, UK, 19-20 June 2000Debate: Does it matter how you lower blood pressure?Debate: Are surrogate end-point studies worth the effort?Debate: The slippery slope of surrogate outcomesAngiotensin receptor blockers in heart failure after the ELITE II trialResults of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?Clinical applicability of molecular biology: the case of the long QT syndrome.Debate: Do all patients with heart failure require implantable defibrillators to prevent sudden death?Debate: Do all patients with heart failure require automatic implantable defibrillators for the prevention of sudden death?Debate: Do all patients with heart failure require implantable defibrillators to prevent sudden death?Low-molecular-weight heparins in the treatment of venous thromboembolismPacing in congestive heart failureMedical therapy versus interventional therapy in hypertropic obstructive cardiomyopathyGene therapy for lipid disordersAn essential guide to the literatureIs clopidogrel superior to aspirin in secondary prevention of vascular disease?Debate: Should the elderly receive thrombolytic therapy or primary angioplasty?Exercise training in heart failureBeta-Adrenergic gene therapy for cardiovascular diseaseDebate: The potential role of estrogen in the prevention of heart disease in women after menopauseDebate: The potential role of estrogen in the prevention of heart disease in women after menopauseDebate: Should the elderly receive thrombolytic therapy, or primary angioplasty, for acute myocardial infarction? The case for primary angioplasty
P1433
Q24531203-4B869B01-198F-4334-9938-97762BBEAE93Q24550555-52DF3653-0D02-4BEA-BE39-EA716F758C1DQ24555155-C05B8393-128B-4B7C-AADA-7C3F48001B9BQ24791524-411EBD06-0A5E-4DAC-BC0E-57A41774B7F4Q24791746-675B4E83-B5CC-4A1F-A3B4-C7F74C43BADBQ24792288-1C318AFC-73E9-4B35-9483-71784D9B7228Q24792307-39E4E928-C260-4451-B233-5FADCF2C505EQ24792327-8FCC2854-A818-4B26-A8AF-DE60C88B8944Q24792342-3C29C1C4-E1F2-41D1-8C9E-A9631E303DF5Q24792362-B7CDB0D0-6924-455F-BE01-88EE748547A1Q24792379-EBD26EE3-E3E7-4FF0-B850-515D8B9D301EQ24792396-83E1BBED-7EAD-41CF-A0E2-9950219B3B7BQ24792413-DC08D598-80FF-4F22-AE8C-564BD6F88E02Q24792433-2E861BDB-A71B-4A68-813A-85327D0A0763Q24792450-CD91683B-BBCE-4A3A-A7A3-0BD0B81AEBE4Q24792466-AB36B83A-B71F-4346-A0E4-BE52350C7BA9Q24792476-A0EBD4E7-D992-448F-87A4-E495FC1576CEQ24792495-94E72C4B-1C11-4109-ABD0-85BF02A99053Q24792519-9E605BBD-4890-4217-97E1-7F83C79E653EQ24792532-E7001B7F-EF26-4CB4-AC17-7AA2F08BC4E0Q24792553-170E0BA2-EAE6-4023-A322-29241E3A1B12Q24792578-F40944A1-8F18-4172-9D01-5556FBDB6CF8Q24792591-14D75CBB-08AA-4770-8997-9060657034EDQ24792611-5BD77D6E-58F4-45CA-BCFC-3330B0A5F3B1Q24792627-84A29CB5-BCCD-4A6D-A829-2BC56364FB11Q24792641-3910969E-7DC4-4800-B566-DDF2A78B6584Q24792660-A5AE4D84-9EB3-4746-BD2A-A91FB63D394BQ24792670-D5345AF5-1ACC-4B92-B27E-5CF58279E05EQ24792692-B6CDBD17-9B34-4FB1-AAA1-FC6FC009E259Q24792710-0D651793-EC5A-4565-B9B7-5A95BD6BC6F9Q24792735-70700F15-D254-4D7F-837E-860300E0983AQ24792755-8421901B-7BC9-4D69-B2B9-4A2F2C715D63Q24792774-EC45508E-B61B-42FD-AE79-2F7BC7D57002Q24792794-4EC2C0E2-B07A-4CC2-A032-DE6645081D50Q24792815-5950C38C-E2A9-49F1-A974-0625F676A30DQ24792831-E0FDA695-DDE9-4677-83DB-CF43FC9B9AB8Q24792845-210EBA80-4DE7-4F9A-98DC-F299CB7254C5Q24792867-723C605C-D373-49BA-961B-136D5C9BF37FQ24792878-087D7228-F020-412D-80D6-3A904D59B432Q24792897-5E7461F1-0409-4EAE-8CF1-AF1EDDB1A904
P1433
description
geneeskundig tijdschrift
@nl
journal
@en
name
Current controlled trials in cardiovascular medicine
@en
Current controlled trials in cardiovascular medicine
@nl
type
label
Current controlled trials in cardiovascular medicine
@en
Current controlled trials in cardiovascular medicine
@nl
altLabel
Current Controlled Trials in Cardiovascular Medicine
@en
prefLabel
Current controlled trials in cardiovascular medicine
@en
Current controlled trials in cardiovascular medicine
@nl
P31
P243
P3181
P1055
P1366
P1476
Current controlled trials in cardiovascular medicine
@en